Seattle Genetics (SGEN), Abbott (ABT) Enter ADC Technology Collaboration
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
Seattle Genetics, Inc. (NASDAQ: SGEN) has entered into a collaboration agreement with Abbott (NYSE: ABT) under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology with antibodies to a single oncology target.
ADCs are monoclonal antibodies that selectively deliver potent anti-cancer agents to tumor cells.
ADCs are monoclonal antibodies that selectively deliver potent anti-cancer agents to tumor cells.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
- Real and RE/MAX Holdings receive court approval for merger
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
